Original Research
6 October 2015

Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study

Publication: Annals of Internal Medicine
Volume 163, Number 7

Abstract

Background:

Cancer is increasingly common among persons with HIV.

Objective:

To examine calendar trends in cumulative cancer incidence and hazard rate by HIV status.

Design:

Cohort study.

Setting:

North American AIDS Cohort Collaboration on Research and Design during 1996 to 2009.

Participants:

86 620 persons with HIV and 196 987 uninfected adults.

Measurements:

Cancer type–specific cumulative incidence by age 75 years and calendar trends in cumulative incidence and hazard rates, each by HIV status.

Results:

Cumulative incidences of cancer by age 75 years for persons with and without HIV, respectively, were as follows: Kaposi sarcoma, 4.4% and 0.01%; non-Hodgkin lymphoma, 4.5% and 0.7%; lung cancer, 3.4% and 2.8%; anal cancer, 1.5% and 0.05%; colorectal cancer, 1.0% and 1.5%; liver cancer, 1.1% and 0.4%; Hodgkin lymphoma, 0.9% and 0.09%; melanoma, 0.5% and 0.6%; and oral cavity/pharyngeal cancer, 0.8% and 0.8%. Among persons with HIV, calendar trends in cumulative incidence and hazard rate decreased for Kaposi sarcoma and non-Hodgkin lymphoma. For anal, colorectal, and liver cancer, increasing cumulative incidence, but not hazard rate trends, were due to the decreasing mortality rate trend (−9% per year), allowing greater opportunity to be diagnosed. Despite decreasing hazard rate trends for lung cancer, Hodgkin lymphoma, and melanoma, cumulative incidence trends were not seen because of the compensating effect of the declining mortality rate.

Limitation:

Secular trends in screening, smoking, and viral co-infections were not evaluated.

Conclusion:

Cumulative cancer incidence by age 75 years, approximating lifetime risk in persons with HIV, may have clinical utility in this population. The high cumulative incidences by age 75 years for Kaposi sarcoma, non-Hodgkin lymphoma, and lung cancer support early and sustained antiretroviral therapy and smoking cessation.

Primary Funding Source:

National Institutes of Health.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Samji HCescon AHogg RSModur SPAlthoff KNBuchacz Ket alNorth American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8:e81355. [PMID: 24367482]  doi: 10.1371/journal.pone.0081355
2.
Wada NJacobson LPCohen MFrench APhair JMuñoz A. Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol. 2013;177:116-25. [PMID: 23287403]  doi: 10.1093/aje/kws321
3.
Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep. 2010;7:69-76. [PMID: 20425560]  doi: 10.1007/s11904-010-0041-9
4.
Shiels MSPfeiffer RMGail MHHall HILi JChaturvedi AKet al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753-62. [PMID: 21483021]  doi: 10.1093/jnci/djr076
5.
Guiguet MBoué FCadranel JLang JMRosenthal ECostagliola DClinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;10:1152-9. [PMID: 19818686]  doi: 10.1016/S1470-2045(09)70282-7
6.
Kesselring AGras LSmit Cvan Twillert GVerbon Ade Wolf Fet al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1–infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2011;52:1458-65. [PMID: 21628488]  doi: 10.1093/cid/cir207
7.
Reekie JKosa CEngsig FMonforte AdWiercinska-Drapalo ADomingo Pet alEuroSIDA Study Group. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer. 2010;116:5306-15.  doi: 10.1002/cncr.25311
8.
Silverberg MJChao CLeyden WAXu LHorberg MAKlein Det al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2551-9. [PMID: 22109347]  doi: 10.1158/1055-9965.EPI-11-0777
9.
Bruyand MThiébaut RLawson-Ayayi SJoly PSasco AJMercié Pet alGroupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis. 2009;49:1109-16. [PMID: 19705973]  doi: 10.1086/605594
10.
Dubrow RSilverberg MJPark LSCrothers KJustice AC. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol. 2012;24:506-16. [PMID: 22759737]
11.
Borges AHDubrow RSilverberg MJ. Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. Curr Opin HIV AIDS. 2014;9:34-40. [PMID: 24225382]  doi: 10.1097/COH.0000000000000025
12.
Borges ÁHSilverberg MJWentworth DGrulich AEFätkenheuer GMitsuyasu Ret alINSIGHT SMART. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS. 2013;27:1433-41. [PMID: 23945504]  doi: 10.1097/QAD.0b013e32835f6b0c
13.
Tesoriero JMGieryic SMCarrascal ALavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14:824-35. [PMID: 18777131]  doi: 10.1007/s10461-008-9449-2
14.
Engsig FNKronborg GLarsen CSPedersen GPedersen CGerstoft Jet al. Lung cancer in HIV patients and their parents: a Danish cohort study. BMC Cancer. 2011;11:272. [PMID: 21702995]  doi: 10.1186/1471-2407-11-272
15.
Rahmanian SWewers MEKoletar SReynolds NFerketich ADiaz P. Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc. 2011;8:313-9. [PMID: 21653534]  doi: 10.1513/pats.201009-058WR
16.
Helleberg MGerstoft JAfzal SKronborg GLarsen CSPedersen Cet al. Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV. AIDS. 2014;28:1499-508. [PMID: 24785952]  doi: 10.1097/QAD.0000000000000283
17.
Kojic EMCu-Uvin S. Update: human papillomavirus infection remains highly prevalent and persistent among HIV-infected individuals. Curr Opin Oncol. 2007;19:464-9. [PMID: 17762572]
18.
Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:S6-9. [PMID: 16352363]
19.
Bagni RWhitby D. Kaposi's sarcoma-associated herpesvirus transmission and primary infection. Curr Opin HIV AIDS. 2009;4:22-6. [PMID: 19339936]  doi: 10.1097/COH.0b013e32831add5a
20.
Simard EPPfeiffer RMEngels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2011;117:1089-96. [PMID: 20960504]  doi: 10.1002/cncr.25547
21.
Simard EPPfeiffer RMEngels EA. Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med. 2010;170:1337-45. [PMID: 20696958]  doi: 10.1001/archinternmed.2010.253
22.
Bedimo RChen RYAccortt NARaper JLLinn CAllison JJet al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis. 2004;39:1380-4. [PMID: 15494916]
23.
Engels EAPfeiffer RMGoedert JJVirgo PMcNeel TSScoppa SMet alHIV/AIDS Cancer Match Study. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20:1645-54. [PMID: 16868446]
24.
Grulich AEvanLeeuwen MTFalster MOVajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59-67. [PMID: 17617273]
25.
Shiels MSCole SRKirk GDPoole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52:611-22. [PMID: 19770804]  doi: 10.1097/QAI.0b013e3181b327ca
26.
Patel PHanson DLSullivan PSNovak RMMoorman ACTong TCet alAdult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148:728-36. [PMID: 18490686]
27.
Robbins HAShiels MSPfeiffer RMEngels EA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS. 2014;28:881-90. [PMID: 24300545]  doi: 10.1097/QAD.0000000000000163
28.
Patel PArmon CChmiel JSBrooks JTBuchacz KWood Ket al. Factors associated with cancer incidence and with all-cause mortality after cancer diagnosis among human immunodeficiency virus-infected persons during the combination antiretroviral therapy era. Open Forum Infect Dis. 2014;1:ofu012. [PMID: 25734086]  doi: 10.1093/ofid/ofu012
29.
Fine JPGray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
30.
Kalbfleisch JDPrentice RL. The Statistical Analysis of Failure Time Data. New York: J Wiley; 1980.
31.
Allignol ASchumacher MWanner CDrechsler CBeyersmann J. Understanding competing risks: a simulation point of view. BMC Med Res Methodol. 2011;11:86. [PMID: 21639902]  doi: 10.1186/1471-2288-11-86
32.
Latouche AAllignol ABeyersmann JLabopin MFine JP. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol. 2013;66:648-53. [PMID: 23415868]  doi: 10.1016/j.jclinepi.2012.09.017
33.
Gange SJKitahata MMSaag MSBangsberg DRBosch RJBrooks JTet al. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol. 2007;36:294-301. [PMID: 17213214]
34.
Korn ELGraubard BIMidthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997;145:72-80. [PMID: 8982025]
35.
Arias E. United States life tables, 2010. Natl Vital Stat Rep. 2014;63:1-63. [PMID: 25383611]
36.
Lau BGange SJMoore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr. 2007;44:179-87. [PMID: 17075385]
37.
Gaynor JJFeuer EJTan CCWu DHLittle CRStraus DJet al. On the use of cause-specific failure and conditional failure probabilities—examples from clinical oncology data. J Am Stat Assoc. 1993;88:400-9.
38.
Efron B. An Introduction to the Bootstrap. London, UK: Chapman & Hall/CRC; 1993.
39.
Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69:239-41.
40.
Lau BCole SRGange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170:244-56. [PMID: 19494242]  doi: 10.1093/aje/kwp107
41.
World Health Organization. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Volume 90—Human Papillomaviruses. Lyon, France: International Agency for Research on Cancer; 2007. Accessed at http://monographs.iarc.fr/ENG/Monographs/vol90/mono90.pdf on 10 August 2015.
42.
Silverberg MJLau BJustice ACEngels EGill MJGoedert JJet alNorth American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54:1026-34. [PMID: 22291097]  doi: 10.1093/cid/cir1012
43.
Silverberg MJChao CLeyden WAXu LTang BHorberg MAet al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009;23:2337-45. [PMID: 19741479]  doi: 10.1097/QAD.0b013e3283319184
44.
Piketty CSelinger-Leneman HBouvier AMBelot AMary-Krause MDuvivier Cet al. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the French hospital database on HIV. J Clin Oncol. 2012;30:4360-6. [PMID: 23091098]  doi: 10.1200/JCO.2012.44.5486
45.
Hleyhel MHleyhel MBouvier AMBelot ATattevin PPacanowski Jet alCancer Risk Group of the French Hospital Database on HIV (FHDH-ANRS CO4). Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort. AIDS. 2014;28:2109-18. [PMID: 25265077]  doi: 10.1097/QAD.0000000000000382
46.
Worm SWBower MReiss PBonnet FLaw MFätkenheuer Get alD:A:D Study Group. Non-AIDS defining cancers in the D:A:D Study—time trends and predictors of survival: a cohort study. BMC Infect Dis. 2013;13:471. [PMID: 24106926]  doi: 10.1186/1471-2334-13-471
47.
Moorman ACGordon SCRupp LBSpradling PRTeshale EHLu Met alChronic Hepatitis Cohort Study Investigators. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. Clin Infect Dis. 2013;56:40-50. [PMID: 22990852]  doi: 10.1093/cid/cis815
48.
Edwards BKNoone AMMariotto ABSimard EPBoscoe FPHenley SJet al. Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290-314. [PMID: 24343171]  doi: 10.1002/cncr.28509
49.
Stock CHaug UBrenner H. Population-based prevalence estimates of history of colonoscopy or sigmoidoscopy: review and analysis of recent trends. Gastrointest Endosc. 2010;71:366-381. [PMID: 19846082]  doi: 10.1016/j.gie.2009.06.018
50.
Jemal AThun MJRies LAHowe HLWeir HKCenter MMet al. Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100:1672-94. [PMID: 19033571]  doi: 10.1093/jnci/djn389
51.
Auluck AHislop GBajdik CPoh CZhang LRosin M. Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (HPV)-related and HPV-unrelated sites in a multicultural population: the British Columbia experience. Cancer. 2010;116:2635-44. [PMID: 20336792]  doi: 10.1002/cncr.25087
52.
Chaturvedi AKEngels EAAnderson WFGillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26:612-9. [PMID: 18235120]  doi: 10.1200/JCO.2007.14.1713
53.
Chaturvedi AKEngels EAPfeiffer RMHernandez BYXiao WKim Eet al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294-301. [PMID: 21969503]  doi: 10.1200/JCO.2011.36.4596
54.
Franceschi SMaso LDRickenbach MPolesel JHirschel BCavassini Met al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer. 2008;99:800-4. [PMID: 18665172]  doi: 10.1038/sj.bjc.6604520
55.
Polesel JClifford GMRickenbach MDalMaso LBattegay MBouchardy Cet alSwiss HIV Cohort Study. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS. 2008;22:301-6. [PMID: 18097233]
56.
Hleyhel MBelot ABouvier AMTattevin PPacanowski JGenet Pet alFrench Hospital Database on HIV–ANRS CO4 Cohort. Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis. 2013;57:1638-47. [PMID: 23899679]  doi: 10.1093/cid/cit497
57.
Hall ECPfeiffer RMSegev DLEngels EA. Cumulative incidence of cancer after solid organ transplantation. Cancer. 2013;119:2300-8. [PMID: 23559438]  doi: 10.1002/cncr.28043
58.
Moyer VAU.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160:330-8. [PMID: 24378917]  doi: 10.7326/M13-2771
59.
Sigel KWisnivesky JShahrir SBrown STJustice AKim Jet al. Findings in asymptomatic HIV-infected patients undergoing chest computed tomography testing: implications for lung cancer screening. AIDS. 2014;28:1007-14. [PMID: 24401647]  doi: 10.1097/QAD.0000000000000189
60.
U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:627-37. [PMID: 18838716]
61.
Wells JSHolstad MMThomas TBruner DW. An integrative review of guidelines for anal cancer screening in HIV-infected persons. AIDS Patient Care STDS. 2014;28:350-7. [PMID: 24936878]  doi: 10.1089/apc.2013.0358
62.
U.S. Food and Drug Administration. Gardasil approved to prevent anal cancer [news release]. Silver Spring, MD: U.S. Food and Drug Administration; 22 December 2010. Accessed at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm237941.htm on 20 April 2015.
63.
Kahn JAXu JKapogiannis BGRudy BGonin RLiu Net al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis. 2013;57:735-44. [PMID: 23667266]  doi: 10.1093/cid/cit319
64.
Kojic EMKang MCespedes MSUmbleja TGodfrey CAllen RTet al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis. 2014;59:127-35. [PMID: 24723284]  doi: 10.1093/cid/ciu238
65.
Wilkin TLee JYLensing SYStier EAGoldstone SEBerry JMet al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010;202:1246-53. [PMID: 20812850]  doi: 10.1086/656320
66.
Kaplan JEBenson CHolmes KKBrooks JTPau AMasur HCenters for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1-207; quiz CE1-4. [PMID: 19357635]
67.
Osinusi ATownsend KKohli ANelson ASeamon CMeissner EGet al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313:1232-9. [PMID: 25706232]  doi: 10.1001/jama.2015.1373
68.
Sulkowski MSEron JJWyles DTrinh RLalezari JWang Cet al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313:1223-31. [PMID: 25706092]  doi: 10.1001/jama.2015.1328
69.
Overton ETKitch DBenson CAHunt PWStein JHSmurzynski Met al. Effect of statin therapy in reducing the risk of serious non–AIDS-defining events and nonaccidental death. Clin Infect Dis. 2013;56:1471-9. [PMID: 23386631]  doi: 10.1093/cid/cit053
70.
Galli LSpagnuolo VPoli ASalpietro SGianotti NCossarini Fet al. Use of statins and risk of AIDS-defining and non–AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy. AIDS. 2014;28:2407-15. [PMID: 25160933]  doi: 10.1097/QAD.0000000000000443
71.
Chao CXu LAbrams DITowner WJHorberg MALeyden WAet al. HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. AIDS. 2011;25:1771-7. [PMID: 21681055]  doi: 10.1097/QAD.0b013e328349c67a
72.
Ganesan ACrum-Cianflone NHiggins JQin JRehm CMetcalf Jet al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011;203:756-64. [PMID: 21325137]  doi: 10.1093/infdis/jiq115
73.
U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services; 2014:151-86.
74.
Althoff KNGange SJ. A critical epidemiological review of cardiovascular disease risk in HIV-infected adults: the importance of the HIV-uninfected comparison group, confounding, and competing risks [Letter]. HIV Med. 2013;14:191-2. [PMID: 23368691]  doi: 10.1111/hiv.12007
75.
Park LSTate JPRodriguez-Barradas MCRimland DGoetz MBGibert Cet al. Cancer incidence in HIV-infected versus uninfected veterans: comparison of cancer registry and ICD-9 code diagnoses. J AIDS Clin Res. 2014;5:1000318. [PMID: 25580366]

Information & Authors

Information

Published In

cover image Annals of Internal Medicine
Annals of Internal Medicine
Volume 163Number 76 October 2015
Pages: 507 - 518

History

Published online: 6 October 2015
Published in issue: 6 October 2015

Keywords

Authors

Affiliations

Michael J. Silverberg, PhD, MPH
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Bryan Lau, PhD, MHS
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Chad J. Achenbach, MD, MPH
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Yuezhou Jing, MS
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Keri N. Althoff, PhD, MPH
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Gypsyamber D'Souza, PhD
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Eric A. Engels, MD, MPH
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Nancy A. Hessol, MSPH
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
John T. Brooks, MD
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Ann N. Burchell, PhD, MSc
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
M. John Gill, MB ChB, MSc
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
James J. Goedert, MD
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Robert Hogg, PhD
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Michael A. Horberg, MD, MAS
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Gregory D. Kirk, MD, PhD, MPH
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Mari M. Kitahata, MD, MPH
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Philip T. Korthuis, MD, MPH
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
William C. Mathews, MD, MSPH
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Angel Mayor, MD, MSc
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Sharada P. Modur, PhD
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Sonia Napravnik, PhD
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Richard M. Novak, MD
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Pragna Patel, MD, MPH
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Anita R. Rachlis, MD, MEd
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Timothy R. Sterling, MD
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
James H. Willig, MD, MSPH
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Amy C. Justice, MD, PhD
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Richard D. Moore, MD, MHS
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
Robert Dubrow, MD, PhD
From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada;
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico;
School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut.
for the North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS
Grant Support: By the National Institutes of Health (grants U01-AI069918, U01-AA013566, U01-AA020790, U01-AI31834, U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004, U01-AI35039, U01-AI35040, U01-AI35041, U01-AI35042, UM1-AI35043, U01-AI37613, U01-AI37984, U01-AI38855, U01-AI38858, U01-AI42590, U01-AI68634, U01-AI68636, U01-AI69432, U01-AI69434, U01-DA036935, U01-HD32632, U10-EY08052, U10-EY08057, U10-EY08067, U24-AA020794, U54-MD007587, UL1-RR024131, UL1-TR000083, F31-DA037788, G12- MD007583, K01-AI071754, K01-AI093197, K23-EY013707, K24-DA00432, K24-AI065298, KL2-TR000421, MO1-RR-00052, N02-CP55504, P30-AI027763, P30-AI094189, P30-AI27757, P30-AI27767, P30-AI036219, P30-AI50410, P30-AI54999, P30-MH62246, R01-AA16893, R01-CA165937, R01-DA04334, R01-DA11602, R01-DA12568, R24-AI067039, R56-AI102622, Z01-CP010214, and Z01-CP010176); Centers for Disease Control and Prevention (contract CDC200-2006-18797); Agency for Healthcare Research and Quality (contract 90047713); Health Resources and Services Administration (contract 90051652); Canadian Institutes of Health Research (grants TGF-96118, HCP-97105, CBR-86906, and CBR-94036); Canadian Institutes of Health Research New Investigator award (Dr. Burchell); Ontario Ministry of Health and Long Term Care; and the government of Alberta, Canada. Additional support was provided by the Intramural Research Program of the National Cancer Institute and the National Institutes of Health.
Disclosures: Dr. Silverberg reports grants from Pfizer and grants from Merck outside the submitted work. Dr. Lau reports grants from National Institutes of Health during the conduct of the study. Dr. Althoff reports grants from National Institutes of Health during the conduct of the study and personal fees from Gilead Sciences outside the submitted work. Ms. Hessol reports grants from the National Institutes of Health during the conduct of the study. Dr. Horberg reports grants from the National Institute of Allergy and Infectious Diseases during the conduct of the study. Dr. Mathews reports grants from National Institutes of Health during the conduct of the study. Dr. Novak reports other from Merck, Gilead, GlaxoSmithKline, Genosea, and Nordique outside the submitted work. Dr. Rachlis reports grants from the Ontario HIV Treatment Network for the Ontario Cohort Study during the conduct of the study. Dr. Sterling reports grants from the National Institutes of Health during the conduct of the study. Dr. Moore reports grants from the National Institutes of Health during the conduct of the study. Dr. Dubrow reports grants from the National Cancer Institute during the conduct of the study. Authors not named here have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M14-2768.
Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that she has no financial relationships or interests to disclose. Darren B. Taichman, MD, PhD, Executive Deputy Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interest to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Catharine B. Stack, PhD, MS, Deputy Editor for Statistics, reports that she has stock holdings in Pfizer.
Reproducible Research Statement: Study protocol: Available at www.naaccord.org. Statistical code and data set: Available from Dr. Lau (e-mail, [email protected]).
Corresponding Author: Michael J. Silverberg, PhD, MPH, Research Scientist, Kaiser Permanente Division of Research, 2000 Broadway, 2nd Floor, Oakland, CA 94612; e-mail, [email protected].
Current Author Addresses: Dr. Silverberg: Research Scientist, Kaiser Permanente Division of Research, 2000 Broadway, 2nd Floor, Oakland, CA 94612.
Dr. Lau: Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Room E7150, Baltimore, MD 21205.
Dr. Achenbach: Division of Infectious Diseases, Center for Global Health, Northwestern University, 645 North Michigan Avenue, Suite 1058, Chicago, IL 60611.
Mr. Jing: Johns Hopkins Bloomberg School of Public Health, 111 Market Place, Suite 906, Baltimore, MD 21202.
Dr. Althoff: Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Room E7137, Baltimore, MD 21205.
Dr. D'Souza: Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Room E6132B, Baltimore, MD 21205.
Dr. Engels: Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Room 6E226 MSC 9767, Bethesda, MD 20892.
Ms. Hessol: Department of Medicine, University of California, San Francisco, 3333 California Street, Suite 420, San Francisco, CA 94143.
Dr. Brooks: Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Office of Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Mailstop E-45, Atlanta, GA 30329-4018.
Dr. Burchell: Ontario HIV Treatment Network, 1300 Yonge Street, Suite 600, Toronto, Ontario M4T 1X3, Canada.
Mr. Gill: Southern Alberta HIV Clinic, Sheldon M. Chumir Health Centre, #3223, 1213 4th Street Southwest, Calgary, Alberta T2R 0X7, Canada.
Dr. Goedert: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Shady Grove, Room 6E106, Bethesda, MD 20892.
Dr. Hogg: BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608–1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada.
Dr. Horberg: Mid-Atlantic Permanente Research Institute, 2101 East Jefferson Street, 3 East, Rockville, MD 20852.
Dr. Kirk: Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Room E6533, Baltimore, MD 21205.
Dr. Kitahata: University of Washington Center for AIDS Research, 325 Ninth Avenue, Box 359931, Seattle, WA 98104-2499.
Dr. Korthuis: Oregon Health and Science University, 3181 SW Sam Jackson Park Road, L475, Portland, OR 97239-3098.
Dr. Mathews: University of California, San Diego Owen Clinic, University of California, San Diego Health System, University of California, San Diego Medical Center, 8681 200 West Arbor Drive, San Diego, CA 92103.
Dr. Mayor: Universidad Central del Caribe, PO Box 60327, Bayamón, PR 00960-6032.
Dr. Modur: Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Room E7014, Baltimore, MD 21205.
Dr. Napravnik: University of North Carolina School of Medicine, CB#; 7215, 130 Mason Farm Road, 2101 Bioinformatics Building, Chapel Hill, NC 27599-7215.
Dr. Novak: Department of Medicine, University of Illinois, Chicago, 808 South Wood Street, Room 888, CSN (MC 735), Chicago, IL 60612.
Dr. Patel: Centers for Disease Control and Prevention, Center of Global Health, Non-Communicable Diseases Unit, 1600 Clifton Road, MS E-93, Atlanta, GA 30333.
Dr. Rachlis: Sunnybrook Health Sciences Centre, Infectious Diseases Division, 2075 Bayview Avenue, Suite B1-03, Toronto, Ontario M4N 3M5, Canada.
Dr. Sterling: Vanderbilt University Medical Center, Section of Infectious Disease, A2200 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232-0146.
Dr. Willig: University of Alabama at Birmingham, 1900 University Boulevard, THT 229, Birmingham, AL 35294.
Dr. Justice: Veterans Affairs Connecticut Healthcare System, 950 Campbell Avenue, 11-ACSLG, West Haven, CT 06516.
Dr. Moore: Johns Hopkins University, 1830 East Monument Street, Room 8059, Baltimore, MD 21287.
Dr. Dubrow: Yale School of Public Health, PO Box 208034, New Haven, CT 06520-8034.
Author Contributions: Conception and design: M.J. Silverberg, B. Lau, C.J. Achenbach, M.J. Gill, M.A. Horberg, R. Dubrow.
Analysis and interpretation of the data: M.J. Silverberg, B. Lau, C.J. Achenbach, Y. Jing, J.T. Brooks, M.J. Gill, J.J. Goedert, R. Hogg, M.A. Horberg, G.D. Kirk, A. Mayor, S. Napravnik, P. Patel, A.R. Rachlis, T.R. Sterling, J.H. Willig, A.C. Justice, R.D. Moore, R. Dubrow.
Drafting of the article: M.J. Silverberg, B. Lau, C.J. Achenbach, Y. Jing, G. D'Souza, N.A. Hessol, J.T. Brooks, M.J. Gill, A. Mayor, R.D. Moore, R. Dubrow.
Critical revision of the article for important intellectual content: M.J. Silverberg, B. Lau, K.N. Althoff, G. D'Souza, E.A. Engels, N.A. Hessol, J.T. Brooks, A.N. Burchell, M.J. Gill, J.J. Goedert, R. Hogg, M.A. Horberg, G.D. Kirk, M.M. Kitahata, P.T. Korthuis, A. Mayor, S. Napravnik, R.M. Novak, P. Patel, T.R. Sterling, J.H. Willig, A.C. Justice, R.D. Moore, R. Dubrow.
Final approval of the article: M.J. Silverberg, B. Lau, C.J. Achenbach, Y. Jing, K.N. Althoff, G. D'Souza, E.A. Engels, N.A. Hessol, J.T. Brooks, A.N. Burchell, M.J. Gill, J.J. Goedert, R. Hogg, M.A. Horberg, G.D. Kirk, M.M. Kitahata, P.T. Korthuis, W.C. Mathews, A. Mayor, S.P. Modur, S. Napravnik, R.M. Novak, P. Patel, A.R. Rachlis, T.R. Sterling, J.H. Willig, A.C. Justice, R.D. Moore, R. Dubrow.
Provision of study materials or patients: M.J. Silverberg, N.A. Hessol, J.T. Brooks, M.J. Gill, J.J. Goedert, G.D. Kirk, W.C. Mathews, S. Napravnik, R.M. Novak, A.R. Rachlis, J.H. Willig, A.C. Justice, R.D. Moore.
Statistical expertise: B. Lau, Y. Jing, K.N. Althoff, S. Napravnik.
Obtaining of funding: M.J. Silverberg, M.J. Gill, J.J. Goedert, A.C. Justice, R.D. Moore, R. Dubrow.
Administrative, technical, or logistic support: C.J. Achenbach, A.N. Burchell, M.J. Gill, S.P. Modur, A.R. Rachlis, J.H. Willig, A.C. Justice.
Collection and assembly of data: M.J. Silverberg, C.J. Achenbach, K.N. Althoff, N.A. Hessol, A.N. Burchell, M.J. Gill, R. Hogg, M.A. Horberg, G.D. Kirk, M.M. Kitahata, P.T. Korthuis, S. Napravnik, R.M. Novak, A.R. Rachlis, T.R. Sterling, J.H. Willig, A.C. Justice, R.D. Moore.
* Drs. Silverberg and Lau contributed equally to this work.
† For members of the North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS, see Appendix 1.

Metrics & Citations

Metrics

Citations

View More

Get Access

Login Options:
Purchase

You will be redirected to acponline.org to sign-in to Annals to complete your purchase.

Create your Free Account

You will be redirected to acponline.org to create an account that will provide access to Annals.

View options

PDF/ePub

View PDF/ePub

Related in ACP Journals

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media